Immunovant Inc [IMVT] stock prices are up 2.54% to $18.59 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The IMVT shares have gain 13.22% over the last week, with a monthly amount glided 15.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Jefferies started tracking the stock with Hold rating on March 03, 2025, and set its price target to $20. On January 03, 2025, downgrade downgraded it’s rating to Peer Perform. Oppenheimer reiterated its recommendation of a Outperform and raised its price target to $53 on October 09, 2024. Oppenheimer started tracking with a Outperform rating for this stock on March 28, 2024, and assigned it a price target of $50. In a note dated March 13, 2024, Goldman initiated an Buy rating and provided a target price of $50 on this stock.
The stock price of Immunovant Inc [IMVT] has been fluctuating between $12.72 and $34.47 over the past year. Currently, Wall Street analysts expect the stock to reach $42.83 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $18.59 at the most recent close of the market. An investor can expect a potential return of 130.39% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.16 points at the first support level, and at 17.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.86, and for the 2nd resistance point, it is at 19.13.
Ratios To Look Out For
It’s worth pointing out that Immunovant Inc [NASDAQ:IMVT]’s Current Ratio is 11.16. On the other hand, the Quick Ratio is 11.16, and the Cash Ratio is 10.38.
Transactions by insiders
Recent insider trading involved Geffner Michael, Chief Medical Officer, that happened on Jul 09 ’25 when 1160.0 shares were sold. Chief Technology Officer, Stout Jay S completed a deal on Jul 09 ’25 to sell 1519.0 shares. Meanwhile, Officer WILLIAM MACIAS bought 30000.0 shares on Jun 25 ’25.
